4arthritisinfo.co.uk Rotating Header Image

Medarex Announces Primary Endpoint Achieved In MDX-1100 Anti-IP-10 Antibody Phase 2 Trial For Rheumatoid Arthritis (Medical News Today)

May 15th, 2009
by Guest Author.

Medarex, Inc. (Nasdaq: MEDX) announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate successfully met its primary endpoint.

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Propeller
  • StumbleUpon
  • Technorati
  • TwitThis

Posted in: Arthritis.

← Go! New York Report: Dieting And Arthritis (WCBS-TV New York)
Arthritis: Walking is good medicine (Greater Milwaukee Today) →

Comments are closed.